PARDEEP BHATIA, Ph.D.

** ******** ***

Farmington, CT-06032

Ph: 860-***-****

Email: ac2hnm@r.postjobfree.com

VISA STATUS: US CITIZEN

OBJECTIVE

Seeking Scientific/ Technical Director or Scientific Consultant in the government or private enterprise.. Comprehensive background in project designing, evaluating, and implementing novel methods, assay development, third- party software packages, grants, and report writing. Superior communication, analytical, management, and leadership skills.Advanced knowledge of Oncology, immunology, virology and biomedical sciences with a focus on molecular medicine, embryonic context, cyber-medicine or futuristic cosmic medicine etc. In addition, good knowledge of solar sciences, physics, chemistry and nano sciences in the above mentioned context. Focus on both conventional and non-conventional natural science and concepts and their implementation and execution. Superior interpersonal and presentation/written communication skills, leadership qualities with organizing and grant awards ability both from national and international sources., Team work and excellent computer knowledge both in Mac and Windows environment.

EXECUTIVE CAPABILITIES

An accomplished scientist with fifteen years experience in Oncology/ in the above mentioned context.

Exceptional ability to create novel ideas and their execution through conventional and non-conventional Natural Science principles,

Business and management skills, self-motivated, enthusiastic, superior interpersonal and verbal/written communication skills.

Proven ability in dissemination of scientific information, review of scientific material, scientific writing and technical presentations.

Organizing and administrative ability, team work and excellent computer knowledge in both Mac and Windows.

EDUCATIONAL QUALIFICATION.

Ph.D. Immunology-Oncology, Department of Zoology, BanarasHinduUniversity, Varanasi, India (1981-1985)

M.Sc (Hons. Sch.) Biology, GuruNanakDevUniversity, Amritsar, India (1980-1981).

B.Sc (Hons. Sch.) Biology, GuruNanakDevUniversity, Amritsar, India (1978-1980).

SCIENTIFIC EXPERIENCE (CHRONOLOGICAL ORDER OF THE POSTS OCCUPIED):

All my professional positions in science have been held OVERSEAS in the USA, UK, CANADA and DENMARK. The chronological order is given below.

Medical Writer, Brite BioMed, LLC, Farmington, CT, USA Nov 2007-Present

Organizing the company affairs such as marketing and establishing clients. Writing, educating and evaluating scientific manuscripts, papers and monographs.

Consultant, Strategic Health Care Services, Columbus, OH Apr 2007-Aug 2007

Writing, editing and evaluating scientific manuscripts and grants.

Senior Postdoctoral Fellow, University of Connecticut Health Center, Farmington, CT Mar 1997-Feb 2005

Principal Investigator: Professor Marc Hansen, Ph.D.

●Investigated the role of TNF super family members RANK and RANKL in Breast Cancer metastasis and Osteosarcoma.

●Developed a novel breast cancer metastasis related diagnostic biomarker, which has an inverse relationship with metastatic phenotype both in Breast Cancer, as well as Osteosarcoma.

●Trained and supervised technical and research staff.

●Experience in grant writing and awarded with CDMRP grant on Breast Cancer from dept of Army and submitted four grants in 2004.

Senior Post Doctoral Fellow, Mayo Clinic, Rochester, MN Mar 1996-Mar 1997

Principal Investigator: Robert Jenkins

●Performed cloning and isolation of Tumor Suppressor genes in Prostate Cancer using Human Genome project techniques such cDNA hybrid selections and RDA etc.

●Submitted three grants in one year.

Post Doctoral Research Assistant, University of Glasgow,

IBLS, UK, University of Glasgow, IBLS, UK Sept 1993-Mar 1995

Principal Investigator: Joanna Wilson

●Investigated role of Epstein Barr Virus Nuclear antigen 1 in Lymphoma in lymphomagenic animals using retroviral insertional mutagenesis or immunoblotting in transgenics.

●Submitted one grant on cloning the EBNA1 associated genes in lymphomagenic transgenic mice.

Research Associate, Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada Sept 1993-Jan 1990

Principal Investigator: Dr. Jim Wright

●Performed cloning of Metastasis Associated Genes using retroviral insertional mutagenesis ( Retroviral oncology).

●Grant submission.

Quintin Hogg Fellow, Royal College of Surgeons of England, London, UK Jul 1988- Jan 1990

Principal Investigators: Professors Newel Johnson and Sidney Chang

●Study of myc and ras mutations in oncogenes in Oral Cancer.

●Generation of novel cell lines, extraction of DNA from human biopsies etc.

Post Doctoral Fellow, Aarhus University, Aarhus, Denmark Feb 1986- Jul 1988

Principal Investigator: Professor Brian F C Clark

●Studied cytokinins and their analogues for their antiaging and anticancer activity.

All India Institute of Medical Sciences, New Delhi, India Sept 1984-Feb 1986

Principal Investigator: Professor Vinod Kochupillai

Studied fetal liver Stem cells and their engraftment in aplastic anemia, AML and other hematological malignancies.

Graduate Student, Banaras Hindu University, Varanasi, India Jul 1981- Jul 1984

Advisor: Dr. AjitSodhi

●Investigated the immuno-potentiating activity of anticancer drug cisplatin on mouse macrophages in vitro.

TECHNICAL EXPERIENCE:

Cell BIOLOGY: Cell culture of epithelial cells, fibroblasts, macrophages, T and B lymphocytes, bone marrow stem cells, generation of cell lines, histology, immunofluorrscence, fluorescent microscopy, confocal microscopy, electron microscopy, immunodiagonostics, autoradiography chromosome preps GBanding and immunosflurescent banding and fluorescent labelling of chromosomes.

MOLECULAR BIOLOGY, VIROLOGY AND GENOMICS: Molecular biology and gene cloning, Genomics, Library construction, immunoscreening, DNA, DNA and Protein gels, PAGE, immunoblotting, PCR, Inverse PCR, RT PCR, RDA, cDNA selection, RNAi, Transgenic and non transgenic preclinical animal model systems, tumor maintenance and transplantation. Biochemical assays, 2D protein gels, enzyme analysis, yeast two hybrid system to study protein protein interactions, virology,gene sequencing and knowledge of genetic software’s and gene analysis.

MEDICAL WRITING EXPERIENCE:

Writing skills:

●Fifteen years experience in medical and technical writing in oncology and biomedical sciences.

●In addition to being a freelance medical writer, I wrote about 16 grants on gene cloning, bone metastasis of breast carcinoma and retroviral insertional mutagenesis at various institutes such as The France Foundation,USA, University of Glasgow, UK, Manitoba Institute of Cell Biology, Winnipeg, Canada, Mayo Clinic, USA, and University of Connecticut Health Center.

●Authored 16 papers and 6-8 grants and needs assessments (short commercial grants) for medical education companies, 8-10 academic grants and about 16 abstracts in peer reviewed journals and symposia.

●Prepared and submitted several posters at national meetings such as AACR, ASBMR, special conferences organized by the Department of ARMY and Paget’s Foundation on Breast Cancer.

●Submitted annual reports on cloning a metastasis associated gene on the institutional grant in Canada and on breast cancer metastasis to the Department of Army Breast Cancer Research Program USA.Reviewed grants from NIH, ACS, and NCI on cancer biology in Feels Institute for Cancer Research and University of Connecticut Health Center, Connecticut (April 1998 till Feb. 2004) and at Manitoba Institute of Cell Biology, Canada (January 1990 till September 1993).

Manuscript Review and Poster Preparation:

Reviewed several papers and PowerPoint presentations and posters while working with Professor Mark Hansen in Feels Institute of Cancer Research and University of Connecticut Health Center since April 1998 till today and at the Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada from January 1990 till February 2005.

AWARDS-EXTRAMURAL FUNDING AND GRANTS SUBMITTED:

Study of Expression of RANK and RANKL in Bone Metastasis of Breast (2005).

Study of Different Subtypes of DCIS in Breast Cancer by Antibody Microarrays (2005).

Study of Osteolytic Metastatic Phenotype in Bone Metastasis of Breast by Antibody Microarrays (2005)

Concept Award from the Department of Defense (DOD) Breast Cancer Research Program for extramural funding (2000).

Cloning the tumor suppressor genes from 7q31 chromosomal region in breast and prostate cancer ( Mayo clinic, 1995)

Cloning the genes for Ataxia telangiectasia AT patients and children

Studies on microsattelite instability in head and neck cancers at the Alberta Cancer board, Alberta, Canada.

Travel Award from the Keystone Symposia for attending Molecular Biology and Bone Disease conference (1999).

Quintin Hogg Fellow at Royal College of Surgeons, London (1988-1989).

Assistant Research Officer, Department of Science and Technology, Government of India, New Delhi, India (1984-1986).

Junior Research Fellow by Dr. Ajit Sodhi from Council of Scientific and Industrial Research, New Delhi, India (1981-1984).

RESEARCH PUBLICATIONS:

1.Bhatia, P., Sanders, M., and Hansen M.F. (2005) Expression of RANKL is inversely related to bone metastatic phenotypein breast cancer. Clin.Cancer.Res. 11:162-165.

2.Drotar M., Silva, S., Barone, E., Campbell., D., Tsimbouri, P., Jurvansuu., J., Bhatia, P., Klein, G., and Wilson, J B. (2003) Epstein-Barr virus nuclear antigen-1 and myc cooperate in lymphomagenesis. Int. J Cancer.106:388-395.

3.Johnson-Pais, T.L., Nellissery, M. J., Ammerman D.G, Pathmanathan, D., Bhatia, P., et al., (2002). Determination of Minimal Region of Loss of Heterozygosity on Chromosome 18q21.33 in Osteosarcoma. Int. J Cancer. 105: 285-288.

4.Hansen M F, Nellisery M J, Bhatia, P (1999). Common Mechanisms of Osteosarcoma and Paget’s disease. J Bone and Mineral Res. 14: 39-44.

5.Bhatia, P., Taylor, W.R., Greenberg, A.H. and Wright, J.A. (1994). Comparison of Glyceraldehyde-3-phosphate dehydrogenase and 28S-Ribosomal RNA gene-expression as RNA loading controls for Northern blot analysis of cell lines of varying malignant potential. Anal. Biochem. 216: 223-226.

6.Chang S.E, Bhatia, P., Johnson, N.W., Morgan, P.R., McCormick, F., Young, B., and Hiorns, L. (1991) Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int. J. Cancer. 48: 409-412.

7.Rattan, S.I.S., Rasmussen, L.M., Bjerring, P., Bhatia, P. and Clark, B.F.C. (1988) Unaltered levels of plasma fibronectin in Alzheimer’s disease. J. Clin. Pathology. 41: 476.

8.Rattan, S.I.S, Cavallius, J., Bhatia, P., and Clark, B.F.C (1987) Protein Elongation factor-1a in ageing rodent brains: In AGEING-A Multifactorial Discussion Eds.Kullari Subha Rao and V. Prabhakar, Association of Gerontology.

9.Rattan, S.I.S., Rasmussen, L.M., Bjerring, P., Bhatia, P. and Clark, B.F.C. (1987). Human plasma fibronectin levels during ageing, Alzheimer’s disease and cancer. In: Advances in Age Research (Eds. E. Steinhagen-Thiessen and D. Knook), TNO Institute for experimental gerontology, Rijswick, The Netherlands.

10.Rattan, S.I.S. and Bhatia, P. (1987). Genetic Engineering: Fact, Fiction and Future. Indo-European Medical Journal (Denmark) 2: 27-29.

11.Bhatia, P., Kochupillai, V., Mehra, N.K. et al. (1987). Studies on engraftment following fetal liver infusion in aplastic anemia and acute leukemia. Thymus. 10: 117-122.

12.Kochupillai, V., Subhadra, S., Francis, S., Nanu, A., Susan, M., Bhatia, P. et al. (1987). Fetal liver infusion in aplastic anemia. Thymus.10: 95-102.

13.Sodhi, A. and Bhatia, P. (1986). In vitro activation of murine macrophages and their increased capacity to lyse target cells after cisplatin treatment. Ind. J. Exp. Biol. 24: 565-572.

14.Sharma, S.P. and Bhatia, P. (1982). Amino acid changes in ageing BruchidsZabrotessubfasciatus (coleoptera). CurrSci, 51: 664-665.

Selected Writings For Medical Education Companies and as a Freelance Medical Writer:

1.Bipolar Disorder (BP) throughout the Life Cycle: Treatments and Treatment

2.Children’s Epilepsy and Therapeutical management

3.Erythropoietin alfa (EPO) in Leukemia and Myelodysplastic Syndrome (MDS)

4.Alzheimer’s Disease, Diagnosis, Therapeutic Measures and Clinical Management.

5.GARDASIL A NEW HOPE IN PRECANCEROUS AND HIGHGRADE CERVICAL CANCERS. (CME CO)

6.Merck’s ZOLINZA™ (vorinostat), Offers Hope for Advanced Cutaneous T-Cell Lymphoma (CME CO)

7.Molecular techniques are the most reliable way of monitoring minimal residual disease (MRD) in Chronic Myelogenous Leukemia. ( CME Company)

Abstracts Published in National and International Meetings: 14

Other Non-academic and commercial publications for CME and as a Freelance Medical Writer: 20-30

Total No. of publications (Academic and Commercial): Around 50

Sample Research Interests and Research Plan

My research interests lie in cell and molecular biology and immunotherapy of cancer and infectious diseases. I have outlined the following objectives of research and development for the next five years:

Background: HIV1 and HIV 2 viruses are the major causes of AIDS worldwide. The disease affects 40 miliion people throughout and it results in the secondary development of hematological malignancies in AIDS patients as post infection syndrome. The following lacuna in the basic biology of HIV makes this virus very virulent requiring thereby the need to understand the biology and therapeutics of the disease.

1.The latency of virus is not completely understood.

2.AIDS progresses in certain patients more strongly than others. Some patients do not respond to the disease progression.

3.Gp 120 viral capsid protein is highly variant in antigencity due to protein folding, resulting in the evasion from the host immunity. Moping of gp120 is required to control the disease.

4.Disease does not affect chimpanzees inspite of the heavy viral load.

5.The direct role of variant HIV strains in hematological malignancies such as Karposi’s sarcoma and lymphomas is not established.

Therefore there is a need to understand the biology and the therapeutic management of the disease. The following plan can be outlined for the next 5 years.

A: The antigenic profiles of CD+4 T lymphocytes will be studied using anti-body microarray system in disease responsive vs non-responsive patients and virally infected and uninfected chimp lymphocytes.

B: Using the same technology different cell types of the lymph node cells will be studied for the viral latency.

C: The antigenic variation of gp120 viral capsid protein folding will be studied elucidating the role of heat shock protein family and the role of packaging proteins in the cell. Specific methods will be investigated to selectively destroy gp120 without affecting the normal cells.

D: The antigenic profiles of the early stages of hematological malignancies will be studied using anti-body microarray system in hematological stem cells and pluripotent cells.

E: Role of AVP’s such as defensins, cariens etc in inactivating the viral particles through binding to the specific viral regions or RNA, micro RNAs, resulting in the activation of viral suppressors. Expanded studies to focus on transcription, translational levels and cell surface as well packaging proteins.

The preliminary data will be generated in 6-12 months and 4 grants will be submitted within one year. These experiments will help us to understand the epidemiology of AIDS and hematological malignancies in addition to its effective therapeutic management.

Breast Cancer Metastasis:

Metastasis establishment of cancer cells at the secondary sites such as bone is one of the lethal causes of cancer cell deaths resulting in the patient morbidity and mortality. I have largely worked in breast cancer metastasis. In addition to that my previous work in India and Scotland was focused on hematological malignancies. My present day renewed research are:

1.Breast cancer and Antiviral proteins (AVP’s) and their role in stimulating TNF super family proteins such as RANK and RANKL and other down stream targets and family members.

2.AVP’stimulation and failure in immune system malignancies such as CML, AML, ALL and aplastic anemia as well as in complex cancer syndromes such as ataxia telangiectasia and if possible in other immune function diseases at the molecular level.

3.Understanding maturation or failure of stem cells in immune function lineage failure in contributing to breast cancer heterogeneity and dedifferentiation in immune system malignanacies and arthritic diseases. So, the following objectives are proposed to address this issue in the breast cancer progression and immune sytem hematological malignancies.

1.To assay for the of the antigenic profiles of stem cells and their downstream lineages of immune cells in differentiation or dedifferentiation in response to AVP stimulation or failure. The characterization of their antigenic profiles can be studied using ab microarray systems.

2.To assay the role of AVP ‘s in immune growth factor release and their abrogation.This will help us to understand the biology of disease progression to a particular type of bone metastasis.

3.To understand the role of AVP proteins in stimulation of glial cells and other brain growth factors with the resemblance to immune system cell lineage or their growth factors. eg, MIF macrophage activating factors have close homology with some brain growth factors and it’s cell lineage. It will be interesting to study the role of AVP in suppressing or counter stimulation if any in the homing of breast cancer cells in cancer and metastasis.

4.To study the vibrational and cyber medicine in AVP stimulation, their protection from brain Mets in cancer homing and metastasis.

5.Role of AVP’s such as defensins, cariens, casiens etc in controlling the cancer by studying their activity at the transcriptional and translational level or at other post translational or DNA fidelity levels. Role of AVP’s in moping up free radicals or promoting protein, RNA, DNA fidelity.

Initial experimentation will be conducted and the grants will be pursued towards the protection from cancer and its eradication.

TEACHING PHILOSOPHY:

I am trained as a scientist with expertise on cell and molecular biology and a Ph.D in immunology-oncology. I got my education as Biologist and later trained as cell and molecular biologist in oncology. I can teach courses in cell and molecular biology, immunology, cell biology, general biology, animal sciences, plant sciences and microbiology both at graduate and undergraduate levels.

My philosophy of teaching is a scientific, inventive and illustrative, supported by graphical presentations, flow charts PowerPoint presentations along with the adequate use of multimedia technology. I believe in active process of teaching rather than a passive one that could be summarized in the following points.

1. Expose the students with the basic concepts in clear, illustrative and lucid style, making use of PowerPoint and graphical presentations, blackboard presentations, flowcharts, figures and line-diagrams using the multimedia technology or the cyber-technology. Initially I expose the students to a basic concept and then develop it slowly by building the argument. Later on I expose them with latest concepts and at the end of the each lecture, I summarize key concepts. At the next day lecture, I try to refresh student memory with previous day key concepts and move onto the next topic.

2. Encourage students to ask questions and give them extra time if needed after office hours. To test the students understanding of the subject, I would like to give them multiple choice and short answer type tests. Students could be evaluated 3-4 times in semester including the final exam.

Contact this candidate